Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UTSPEP: Tegileridine vs sufentanil PCIA after laparoscopic surgery
ChiCTR2500110053Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tegileridine in postoperative nausea and vomiting (PONV) and postoperative pain (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Incidence of PONV within 72 hours after surgery. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
tegileridine
03
Conditions
postoperative nausea and vomiting (PONV)postoperative pain
Beyond the preview
Go deeper on ChiCTR2500110053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110053.